Dilaudid and Injection site extravasation - a phase IV clinical study of FDA data

Summary:

Injection site extravasation is reported as a side effect among people who take Dilaudid (hydromorphone hydrochloride), especially for people who are female, 40-49 old, also take Fentanyl, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Injection site extravasation when taking Dilaudid. It is created by eHealthMe based on reports of 95,518 people who have side effects when taking Dilaudid from the FDA, and is updated regularly.

What is Dilaudid?

Dilaudid has active ingredients of hydromorphone hydrochloride. It is often used in pain. eHealthMe is studying from 96,466 Dilaudid users. Check the latest studies of Dilaudid.

What is Injection site extravasation?

Injection site extravasation (flow of (blood or lymph) from injection site) is found to be associated with 552 drugs and 730 conditions by eHealthMe. Check the latest studies of Injection site extravasation.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

95,518 people reported to have side effects when taking Dilaudid.
Among them, 30 people (0.03%) have Injection site extravasation.

Could Dilaudid cause Injection site extravasation?

Among these 30 people:

What is the gender of people who have Injection site extravasation when taking Dilaudid? *

female: 62.96 %
male: 37.04 %

What is the age of people who have Injection site extravasation when taking Dilaudid? *

What are other drugs people take besides Dilaudid? *

What are other side effects people have besides Injection site extravasation? *

Headache (pain in head): 13 people, 43.33%
Nausea (feeling of having an urge to vomit): 12 people, 40.00%
Fatigue (feeling of tiredness): 11 people, 36.67%
High Blood Pressure: 10 people, 33.33%
Weight Increased: 9 people, 30.00%
Blood Pressure Diastolic Increased: 9 people, 30.00%
Dizziness: 9 people, 30.00%
Infection: 8 people, 26.67%
Diarrhea: 8 people, 26.67%
Weight Decreased: 7 people, 23.33%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 9 people, 30.00%
Weakness: 5 people, 16.67%
Carcinoid Tumor: 5 people, 16.67%
Neuroendocrine Carcinoma Metastatic (cancer tumour that arise from cells of the endocrine (hormonal) and nervous systems and spreads to other part): 5 people, 16.67%
Depression: 4 people, 13.33%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 4 people, 13.33%
Lymphoma (cancer that begins in immune system cells): 4 people, 13.33%
Hiatal Hernia (hernia resulting from the protrusion of part of the stomach through the diaphragm): 3 people, 10.00%
Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 3 people, 10.00%
Colitis (inflammation of colon): 3 people, 10.00%

* Approximation only. Some reports may have incomplete information.

Do you take Dilaudid and have Injection site extravasation?

- Check whether Injection site extravasation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Dilaudid:

Dilaudid (96,466 reports)

Browse all side effects of Dilaudid:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Injection site extravasation:

Injection site extravasation (552 drugs)

Browse all the conditions that are associated with Injection site extravasation:

Injection site extravasation (730 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on hydromorphone hydrochloride (the active ingredients of Dilaudid) and Dilaudid (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.